IL10 and melanoma: Recently, Giunta et al. reported high baseline IFN-γ/IL-10 ratio in peripheral blood mononuclear cells could predict the clinical response and a longer PFS in patients with advanced melanoma treated with either nivolumab or pembrolizumab [74].